Is vaccination against viral hepatitis B safe and immunogenic in patients with rheumatic diseases?
Impressive successes have been achieved in the fight against viral hepatitis B (HBV), but victory over this infection has not yet been achieved. According to various estimates, there are 6–12.5 times more patients with resolved HBV who are carriers of the virus than carriers of the "Australian&...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2024-10-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1649 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849242074248904704 |
|---|---|
| author | G. I. Gridneva B. S. Belov E. S. Aronova |
| author_facet | G. I. Gridneva B. S. Belov E. S. Aronova |
| author_sort | G. I. Gridneva |
| collection | DOAJ |
| description | Impressive successes have been achieved in the fight against viral hepatitis B (HBV), but victory over this infection has not yet been achieved. According to various estimates, there are 6–12.5 times more patients with resolved HBV who are carriers of the virus than carriers of the "Australian" surface antigen HBsAg. The basis for the prevention of HBV is passive and active immunization of the population, but the data on the safety and immunogenicity of this vaccine in patients with rheumatic diseases are contradictory. This review examines the safety and immunogenicity of vaccination against hepatitis B virus (HBV) in patients with immune-inflammatory rheumatic diseases. Vaccination against HBV is indicated for patients at risk of infection and should be carried out before starting antirheumatic therapy, as immunogenicity and efficacy are significantly higher in this case. The necessity of a detailed, targeted medical history collection to clarify the risk of HBV infection before prescribing antirheumatic therapy and clarification of the immune status (presence of HBsAg, antibodies against HBc and HBs) before vaccination is emphasized. |
| format | Article |
| id | doaj-art-9cc75f9e8dd14538bae4f874fc0f2de9 |
| institution | Kabale University |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2024-10-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-9cc75f9e8dd14538bae4f874fc0f2de92025-08-20T03:59:56ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2024-10-0118512112610.14412/1996-7012-2024-5-121-1262728Is vaccination against viral hepatitis B safe and immunogenic in patients with rheumatic diseases?G. I. Gridneva0B. S. Belov1E. S. Aronova2V.A. Nasonova Research Institute of RheumatologV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyImpressive successes have been achieved in the fight against viral hepatitis B (HBV), but victory over this infection has not yet been achieved. According to various estimates, there are 6–12.5 times more patients with resolved HBV who are carriers of the virus than carriers of the "Australian" surface antigen HBsAg. The basis for the prevention of HBV is passive and active immunization of the population, but the data on the safety and immunogenicity of this vaccine in patients with rheumatic diseases are contradictory. This review examines the safety and immunogenicity of vaccination against hepatitis B virus (HBV) in patients with immune-inflammatory rheumatic diseases. Vaccination against HBV is indicated for patients at risk of infection and should be carried out before starting antirheumatic therapy, as immunogenicity and efficacy are significantly higher in this case. The necessity of a detailed, targeted medical history collection to clarify the risk of HBV infection before prescribing antirheumatic therapy and clarification of the immune status (presence of HBsAg, antibodies against HBc and HBs) before vaccination is emphasized.https://mrj.ima-press.net/mrj/article/view/1649rheumatic diseasesimmunosuppressive therapyantirheumatic drugschronic viral hepatitis bscreeningpreventionvaccination |
| spellingShingle | G. I. Gridneva B. S. Belov E. S. Aronova Is vaccination against viral hepatitis B safe and immunogenic in patients with rheumatic diseases? Современная ревматология rheumatic diseases immunosuppressive therapy antirheumatic drugs chronic viral hepatitis b screening prevention vaccination |
| title | Is vaccination against viral hepatitis B safe and immunogenic in patients with rheumatic diseases? |
| title_full | Is vaccination against viral hepatitis B safe and immunogenic in patients with rheumatic diseases? |
| title_fullStr | Is vaccination against viral hepatitis B safe and immunogenic in patients with rheumatic diseases? |
| title_full_unstemmed | Is vaccination against viral hepatitis B safe and immunogenic in patients with rheumatic diseases? |
| title_short | Is vaccination against viral hepatitis B safe and immunogenic in patients with rheumatic diseases? |
| title_sort | is vaccination against viral hepatitis b safe and immunogenic in patients with rheumatic diseases |
| topic | rheumatic diseases immunosuppressive therapy antirheumatic drugs chronic viral hepatitis b screening prevention vaccination |
| url | https://mrj.ima-press.net/mrj/article/view/1649 |
| work_keys_str_mv | AT gigridneva isvaccinationagainstviralhepatitisbsafeandimmunogenicinpatientswithrheumaticdiseases AT bsbelov isvaccinationagainstviralhepatitisbsafeandimmunogenicinpatientswithrheumaticdiseases AT esaronova isvaccinationagainstviralhepatitisbsafeandimmunogenicinpatientswithrheumaticdiseases |